Novo Nordisk scores major legal win that bars many compounded versions of Wegovy, Ozempic
Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn't have insurance coverage for the treatments.
Novo
since
auto-detected in 401 stories
11 days ago
Novo Nordisk scores major legal win that bars many compounded versions of Wegovy, Ozempic
Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn't have insurance coverage for the treatments.
Novo Nordisk scores major legal win that bars many compounded versions of Wegovy, Ozempic
Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn't have insurance coverage for the treatments.
14 days ago
Novo Nordisk shares fall 8% after Eli Lilly obesity drug trial results; European markets move lower
European markets returned from the long Easter weekend on a negative note.
Novo Nordisk shares fall 7% after Eli Lilly obesity drug trial results; European markets move lower
European markets returned from the long Easter weekend on a negative note.
15 days ago
Novo Nordisk shares fall 8% after Eli Lilly obesity drug trial; European markets move lower
European markets returned from the long Easter weekend on a negative note.
Novo Nordisk shares fall 8% after Eli Lilly obesity drug trial; European markets move lower
European markets returned from the long Easter weekend on a negative note.
38 days ago
Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years
The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart disease.
Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years
The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart disease.
Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years
The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart disease.
|← first ← previous page 2 of 5 next → last →|